NASDAQ:MIRM Mirum Pharmaceuticals (MIRM) Stock Price, News & Analysis $113.03 -1.33 (-1.16%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$112.95 -0.08 (-0.07%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Mirum Pharmaceuticals Stock (NASDAQ:MIRM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Mirum Pharmaceuticals alerts:Sign Up Key Stats Today's Range$111.57▼$115.5950-Day Range$92.03▼$128.5752-Week Range$50.25▼$130.00Volume516,939 shsAverage Volume660,891 shsMarket Capitalization$6.89 billionP/E RatioN/ADividend YieldN/APrice Target$143.40Consensus RatingModerate Buy Company Overview Mirum Pharmaceuticals, Inc. is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist. Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage. Maralixibat has achieved regulatory approval in the United States for the treatment of cholestatic pruritus in patients with Alagille syndrome and is under review or in clinical development for other rare cholestatic conditions, including progressive familial intrahepatic cholestasis (PFIC). In addition to its lead compound, Mirum maintains a pipeline of product candidates aimed at expanding the therapeutic options available to patients with orphan liver diseases. Founded in 2016 and headquartered in Brisbane, California, Mirum Pharmaceuticals operates with a patient-centric approach that emphasizes collaboration with advocacy groups and key opinion leaders in hepatology. Under the leadership of President and Chief Executive Officer Derek Chalmers, the company is actively pursuing regulatory approvals and commercial partnerships to bring its therapies to patients in the United States and international markets.AI Generated. May Contain Errors. Read More Mirum Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreMIRM MarketRank™: Mirum Pharmaceuticals scored higher than 63% of companies evaluated by MarketBeat, and ranked 402nd out of 834 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingMirum Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 1 strong buy rating, 13 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialMirum Pharmaceuticals has a consensus price target of $143.40, representing about 26.9% upside from its current price of $113.03.Amount of Analyst CoverageMirum Pharmaceuticals has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Mirum Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Mirum Pharmaceuticals are expected to grow in the coming year, from ($2.01) to $0.13 per share.Price to Book Value per Share RatioMirum Pharmaceuticals has a P/B Ratio of 18.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Mirum Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.01% of the float of Mirum Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverMirum Pharmaceuticals has a short interest ratio ("days to cover") of 10.59, which indicates bearish sentiment.Change versus previous monthShort interest in Mirum Pharmaceuticals has recently decreased by 2.81%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMirum Pharmaceuticals does not currently pay a dividend.Dividend GrowthMirum Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.2 / 5News Sentiment1.07 News SentimentMirum Pharmaceuticals has a news sentiment score of 1.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.91 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Mirum Pharmaceuticals this week, compared to 6 articles on an average week.Search InterestOnly 4 people have searched for MIRM on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.MarketBeat Follows5 people have added Mirum Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Mirum Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,991,928.00 in company stock.Percentage Held by Insiders8.32% of the stock of Mirum Pharmaceuticals is held by insiders.Percentage Held by InstitutionsMirum Pharmaceuticals has minimal institutional ownership at this time.Read more about Mirum Pharmaceuticals' insider trading history. Receive MIRM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mirum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MIRM Stock News HeadlinesMirum Pharmaceuticals (MIRM) Projected to Announce Earnings on ThursdayJuly 23 at 3:31 AM | americanbankingnews.comMirum Advances New Drug Candidate With Fresh Phase 1 Study UpdateJuly 17, 2026 | tipranks.comDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monetary reset tied to executive order 14241 - one he says could draw a sharp dividing line between prepared investors and those left behind. The last time America reset its money - under Nixon in the 1970s - it produced an average of 1,300 new millionaires per day for over 50 years. Stansberry's new documentary names a core group of assets he believes are positioned to surge as Trump's new dollar rolls out. Watch Porter Stansberry's full briefing and get his three steps to prepare before December.July 26 at 1:00 AM | Porter & Company (Ad)Mirum Pharmaceuticals (NASDAQ:MIRM) CFO Eric Bjerkholt Sells 5,000 Shares of StockJuly 9, 2026 | insidertrades.comMirum Pharmaceuticals: This Liver Disease Juggernaut Just Broadened Its PortfolioJuly 4, 2026 | seekingalpha.comJolanda Howe Sells 2,721 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) StockJuly 3, 2026 | insidertrades.comThe Bull Case For Mirum Pharmaceuticals (MIRM) Could Change Following Priority FDA Review Of FOP Drug ZilurgisertibJuly 2, 2026 | finance.yahoo.comIs Mirum Pharmaceuticals, Inc. (MIRM) Emerging as a Rare Disease Growth Story After New FOP Data?June 25, 2026 | insidermonkey.comSee More Headlines MIRM Stock Analysis - Frequently Asked Questions How have MIRM shares performed this year? Mirum Pharmaceuticals' stock was trading at $78.99 at the start of the year. Since then, MIRM stock has increased by 43.1% and is now trading at $113.03. How were Mirum Pharmaceuticals' earnings last quarter? Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) posted its quarterly earnings data on Wednesday, May, 6th. The company reported ($13.43) earnings per share for the quarter, missing the consensus estimate of ($0.75) by $12.68. The business's revenue was up 43.3% compared to the same quarter last year. Read the conference call transcript. When did Mirum Pharmaceuticals IPO? Mirum Pharmaceuticals (MIRM) raised $75 million in an IPO on Thursday, July 18th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Citigroup, Evercore ISI and Guggenheim Securities acted as the underwriters for the IPO and Raymond James and Roth Capital Partners were co-managers. Who are Mirum Pharmaceuticals' major shareholders? Mirum Pharmaceuticals' top institutional investors include Handelsbanken Fonder AB (0.32%), Hennion & Walsh Asset Management Inc. (0.06%) and Contravisory Investment Management Inc. (0.01%). Insiders that own company stock include Patrick J Heron, Christopher Peetz, Lara Longpre, Eric Bjerkholt, Peter Radovich, Pamela Vig, Joanne Quan, Laura Brege, Jolanda Howe, Saira Ramasastry and Michael G Grey. View institutional ownership trends. How do I buy shares of Mirum Pharmaceuticals? Shares of MIRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Mirum Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mirum Pharmaceuticals investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT (). Company Calendar Last Earnings5/06/2026Today7/26/2026Next Earnings (Estimated)7/30/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 MIRM's financial health is in the Green zone, according to TradeSmith. MIRM has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MIRM CIK1759425 Webmirumpharma.com Phone(650) 667-4085FaxN/AEmployees140Year Founded2018Price Target and Rating Average Price Target for Mirum Pharmaceuticals$143.40 High Price Target$185.00 Low Price Target$118.00 Potential Upside/Downside+26.9%Consensus RatingModerate Buy Rating Score (0-4)2.93 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($13.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$23.36 million Net Margins-140.24% Pretax Margin-140.00% Return on Equity-11.28% Return on Assets-3.84% Debt Debt-to-Equity Ratio1.28 Current Ratio2.09 Quick Ratio1.99 Sales & Book Value Annual Sales$521.31 million Price / Sales13.22 Cash Flow$0.05 per share Price / Cash Flow2,217.18 Book Value$6.12 per share Price / Book18.47Miscellaneous Outstanding Shares60,980,000Free Float55,907,000Market Cap$6.89 billion OptionableOptionable Beta0.48 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:MIRM) was last updated on 7/26/2026 by MarketBeat.com Staff. From Our PartnersControl 100 shares without spending thousands of dollarsWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredUniversal basic income is not impossible. It exist (kind of)Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...Freedom Financial | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredBlackRock's $2.8B Clue (most investors missed)BlackRock's new fund on the emerging financial grid hit 2.8 billion in assets in just three months, according ...Awesomely | SponsoredOxford Club Analyst’s Urgent AI WarningAlexander Green, Chief Investment Strategist at The Oxford Club, is sharing a private presentation with a warn...The Oxford Club | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredAugust 6 could be a BIG day for one AI companyOne AI company's revenue has surged 757 percent in the past year, earning it an A rating from Louis Navellier'...InvestorPlace | SponsoredThis tiny piece of glass could be bigger than GPUsJensen Huang says AI can't scale without it. Google Ventures calls it the future of AI compute. Sequoia Capita...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mirum Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mirum Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
